[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656135":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":13,"overallOfficials":13,"centralContacts":13,"locations":22,"responsibleParty":45,"collaborators":13,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":13,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":13,"enrollmentInfo":57,"targetDuration":13,"studyType":60,"phases":13,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":67,"whyStopped":13,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Recurrence-Free Survival","Time, in months, from surgery to the first documented local, regional, or distant recurrence, determined using imaging, pathology, or documented clinical assessment. Participants without recurrence will be censored at their last disease assessment. Death without documented recurrence is not an RFS event; these participants will be censored at their last disease assessment before death. RFS probabilities at 12 and 24 months after surgery will be estimated using the Kaplan-Meier method.","From surgery through December 1, 2025, up to 64 months.",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","RETROSPECTIVE","The source population comprises adults who underwent esophagectomy for esophageal squamous cell carcinoma at the study institution between August 1, 2020, and October 31, 2025. Patients will be identified through institutional medical records, imaging archives, surgical and pathology registries, and existing follow-up records. All patients within this surgical window who received neoadjuvant immunochemotherapy and meet the eligibility criteria will be included. No random sampling will be performed. Documented postoperative outcomes will be reviewed through December 1, 2025.",[19],{"label":20,"type":13,"description":21,"interventionNames":13},"ESCC After Neoadjuvant Immunochemotherapy and Surgery","Patients with histologically confirmed esophageal squamous cell carcinoma who underwent curative esophagectomy between August 1, 2020, and October 31, 2025, after neoadjuvant immunochemotherapy. Existing clinical records, FDG PET\u002FCT findings, surgical pathology reports, and postoperative follow-up records will be reviewed to assess recurrence risk and associated factors. All treatments and examinations were provided as part of routine clinical care and were not assigned by this study.",[23],{"facility":24,"status":13,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Peking University Cancer Hospital","Beijing","Beijing Municipality","100142","China","CN",{"type":31,"coordinates":32},"Point",[33,34],116.39723,39.9075,{"lat":34,"lon":33},[37,42],{"name":38,"role":39,"phone":40,"phoneExt":13,"email":41},"Nan Wu, Doctor","CONTACT","0086-010-88121122","nanwu@bjmu.edu.cn",{"name":43,"role":44,"phone":13,"phoneExt":13,"email":13},"Nan Wu, MD","PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Wu Nan","Professor","100656135","risk-of-esophageal-cancer-returning-after-immunotherapy-chemotherapy-and-surgery-100656135",false,"NCT07822906","Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery","Postoperative Recurrence Risk and Associated Factors in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy","Inclusion Criteria:\n\n* Age 18 years or older at the time of surgery.\n\nHistologically confirmed esophageal squamous cell carcinoma.\n\nReceipt of neoadjuvant immunochemotherapy, defined as an immune checkpoint inhibitor combined with chemotherapy, followed by curative esophagectomy between August 1, 2020, and October 31, 2025.\n\nMicroscopically negative surgical margins (R0 resection), postoperative M0 status confirmed on review using the American Joint Committee on Cancer eighth edition staging system, and verifiable postoperative ypT and ypN categories.\n\nAvailability of FDG PET\u002FCT performed after completion of neoadjuvant treatment and before surgery, together with a verifiable surgery date, recurrence status, and valid follow-up dates. Availability of pretreatment PET\u002FCT is not required.\n\nExclusion Criteria:\n\n* Histology other than esophageal squamous cell carcinoma, R1 or R2 resection.\n\nDeath within 30 days after surgery or absence of any verifiable postoperative outcome follow-up.\n\nMissing essential pathological staging information, or survival data that prevent confirmation of eligibility or determination of the primary outcome despite review of source records. Missing nonessential variables alone will not result in exclusion.","ALL","18 Years",{"count":58,"type":59},100,"ESTIMATED","OBSERVATIONAL","This observational study aims to understand the risk of cancer returning after surgery in people with esophageal squamous cell carcinoma, a type of cancer of the food pipe. It focuses on people who received immunotherapy and chemotherapy before surgery.\n\nResearchers will review existing medical records, scans, reports on tissue removed during surgery, and follow-up information. They will examine when and where cancer returns and which patient characteristics, treatment details, scan findings, and tissue findings are associated with its return.\n\nAll treatment and tests were part of routine care. The study does not assign treatment or require additional scans, tissue collection, or follow-up visits.",[63],"Esophageal Squamous Cell Carcinoma (ESCC)",[65,10,66],"Neoadjuvant Immunochemotherapy","Lymph Node Metastasis","NOT_YET_RECRUITING","2026-09-14",{"date":70,"type":71},"2026-09-16","ACTUAL",{"date":73,"type":59},"2026-10-01",{"date":75,"type":59},"2026-12-31",{"name":5,"class":6},1]